Overview

A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

Status:
Completed
Trial end date:
2017-05-18
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC